ViaDerm-GLP1 has Successfully Completed Phase 1 of the Clinical Studies
ViaDerm-GLP1 is a new class of diabetes medication for type 2 diabetes. It is a transdermal (patch) diabetic medication that uses the aid of a handheld electric device to deliver the medication into the bloodstream.
The Benefits of ViaDerm-GLP1
The benefits of this new medication include no insulin injections, the medication lasts for 13 hours as compared to an insulin injection which typically only lasts six hours and no risk of hypoglycemia.
A statement About ViaDerm-GLP1 from TransPharma
The following information is a statement from the maker of ViaDerm-GLP1 “TransPharma's ViaDerm drug delivery system incorporates a handheld electronic device, which creates microscopic passageways through the outer layer of the skin allowing for transdermal delivery of a wide variety of drugs from a patch. The system provides a cost-effective, easy-to-use, self-administered solution that enables the safe, reproducible and accurate delivery of a broad range of product candidates, including hydrophilic small molecules peptides and proteins.”
This new medication will soon enter the second phase of human clinical trials and hopefully be available on the market in the near future.
Source: TransPharma Medical